MedTrace Logo

LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

NCT00610883 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:

* Induction ends on day 19
* Consolidation ends on day 38 or 42
* Maintenance may include up to 6 cycles

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU

LSA4 intervention includes three phases: induction, consolidation and maintenance

Sponsors & Collaborators

Principal Investigators

  • Tanya Trippett, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00610883 on ClinicalTrials.gov